

# Roberta Zappasodi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5760984/publications.pdf>

Version: 2024-02-01

50  
papers

10,579  
citations

257357

24  
h-index

233338

45  
g-index

53  
all docs

53  
docs citations

53  
times ranked

18277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
2	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , 2017, 551, 512-516.	13.7	854
3	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
4	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. <i>Nature Immunology</i> , 2020, 21, 298-308.	7.0	326
5	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. <i>Immunity</i> , 2021, 54, 1561-1577.e7.	6.6	260
6	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. <i>Nature Communications</i> , 2020, 11, 4011.	5.8	198
7	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. <i>Nature Immunology</i> , 2022, 23, 660-670.	7.0	191
8	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. <i>Nature</i> , 2021, 591, 652-658.	13.7	187
9	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
10	Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. <i>Cancer Research</i> , 2010, 70, 9062-9072.	0.4	126
11	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
12	Non-conventional Inhibitory CD4 <sup>+</sup> Foxp3 <sup>hi</sup> PD-1 <sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
13	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99
14	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. <i>Haematologica</i> , 2008, 93, 1523-1534.	1.7	63
15	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. <i>Cancer Research</i> , 2014, 74, 6248-6259.	0.4	63
16	Tumor-Reactive CD8 <sup>+</sup> Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 8378-8387.	0.4	52
17	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41
18	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1768-1771.	0.6	40

#	ARTICLE	IF	CITATIONS
19	Combination of Alphavirus Replicon Particle-Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 448-458.	1.6	37
20	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	2.2	36
21	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
22	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	3.9	33
23	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	0.6	30
24	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. <i>Archives of Biochemistry and Biophysics</i> , 2020, 690, 108479.	1.4	30
25	Sialidase NEU4 is involved in glioblastoma stem cell survival. <i>Cell Death and Disease</i> , 2014, 5, e1381-e1381.	2.7	27
26	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
27	Fundamental immune oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	13.7	23
28	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. <i>Cell Reports</i> , 2021, 34, 108620.	2.9	21
29	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	2.0	19
30	MAIT and V $\alpha$ 2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
31	Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against Myc-overexpressing human B-cell non-Hodgkin lymphomas. <i>International Journal of Cancer</i> , 2014, 135, 2034-2045.	2.3	18
32	Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. <i>Hematological Oncology</i> , 2018, 36, 360-362.	0.8	15
33	Phase IB Study of G1TR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
34	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
35	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	8
36	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 805195.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <i>Immunotherapy</i> , 2015, 7, 981-997.	1.0	5
38	In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. <i>Methods in Enzymology</i> , 2020, 631, 43-59.	0.4	5
39	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. <i>Science Advances</i> , 2022, 8, eabm4552.	4.7	5
40	To Go or Not to Go? Targeting Tregs Traveling in Tumors. <i>Cancer Research</i> , 2021, 81, 2817-2819.	0.4	4
41	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
42	Serological Identification of HSP105 as a Novel Non-Hodgkin Lymphoma Therapeutic Target. <i>Blood</i> , 2010, 116, 463-463.	0.6	2
43	MAIT and VÎ2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome. <i>Blood</i> , 2021, 138, 331-331.	0.6	2
44	Supporting the next generation of scientists to lead cancer immunology research. <i>Cancer Immunology Research</i> , 2021, 9, canimm.0519.2021.	1.6	1
45	Cytotoxic Activity of Histone Deacetylase Inhibitor ITF2357 on Burkitt's Lymphoma Cell Lines Is Associated to Micro-RNA Modulation and Transglutaminase 2 Restoration.. <i>Blood</i> , 2008, 112, 1594-1594.	0.6	1
46	HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1562-1562.	0.6	1
47	619 Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy. , 2021, 9, A649-A649.		1
48	493 Tired and hungry: a potential role for CD47 in T cell exhaustion. , 2020, , .		1
49	MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma. <i>Blood</i> , 2011, 118, 2729-2729.	0.6	0
50	Non-Hodgkin's Lymphomas. , 2012, , 115-157.		0